Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer

• Published in: Scientific reports Vol. 9; no. 1; pp. 13924 - 9
• Main Authors: Asare-Werehene, Meshach, Communal, Laudine, Carmona, Euridice, Le, Tien, Provencher, Diane, Mes-Masson, Anne-Marie, Tsang, Benjamin K.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.09.2019; Nature Publishing Group
• Subjects: 631/67/1517/1709; 631/67/1857; 82; Actin; Adult; Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor - blood; Cell death; Cisplatin; Disease detection; Enzyme-linked immunosorbent assay; Female; Gelsolin; Gelsolin - blood; Humanities and Social Sciences; Humans; Medical prognosis; Middle Aged; multidisciplinary; Ovarian cancer; Ovarian Neoplasms - blood; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Patients; Preoperative Period; Regression analysis; Science; Science (multidisciplinary); Statistical analysis; Survival Analysis
• DOI: 10.1038/s41598-019-50436-1
• ISSN: 2045-2322

Ovarian cancer (OVCA) patients with suboptimal residual disease (RD) and advanced stages have poor survival. pGSN is an actin binding protein which protects OVCA cells from cisplatin-induced death. There is an urgent need to discover reliable biomarkers to optimize individualized treatment recommendations. 99 plasma samples with pre-determined CA125 were collected from OVCA patients and pGSN assayed using sandwich-based ELISA. Associations between CA125, pGSN and clinicopathological parameters were examined using Fisher’s exact test, T test and Kruskal Wallis Test. Univariate and multivariate Cox proportional hazard models were used to statistically analyze clinical outcomes. At 64 µg/ml, pGSN had sensitivity and specificity of 60% and 60% respectively, for the prediction of RD where as that of CA125 at 576.5 U/mL was 43.5% and 56.5% respectively. Patients with stage 1 tumor had increased levels of pre-operative pGSN compared to those with tumor stage >1 and healthy subjects ( P  = 0.005). At the value of 81 µg/mL, pGSN had a sensitivity and specificity of 75% and 78.4%, respectively for the detection of early stage OVCA. At the value of 0.133, the Indicator of Stage 1 OVCA (ISO1) provided a sensitivity of 100% at a specificity of 67% (AUC, 0.89; P  < 0.001). In the multivariate Cox regression analysis, pGSN (HR, 2.00; CI, 0.99–4.05; P  = 0.05) was an independent significant predictor of progression free survival (PFS) but not CA125 (HR, 0.68; CI, 0.41–1.13; P  = 0.13). Pre-operative circulating pGSN is a favorable and independent biomarker for early disease detection, RD prediction and patients’ prognosis.